NCT02056730View on ClinicalTrials.gov

The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Hyperparathyroidism, Secondary
Interventions
DRUG

calcium sensing receptor agonist

For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).

Trial Locations (1)

10330

Chulalongkorn Memorial Hospital, Bangkok

All Listed Sponsors
lead

Chulalongkorn University

OTHER

NCT02056730 - The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid | Biotech Hunter | Biotech Hunter